Over the last 20 years, biological drugs have changed the therapeutic prospect for chronic inflammatory bowel diseases both in the adult and in the child.1 Infliximab was the first drug that, when its patent expired, had biosimilars authorised by EMA, CT-P13 and SB2 respectively in 2013 and 2016.2...